An efflux-susceptible antibiotic-adjuvant with systemic efficacy against mouse infections

Abstract

Scarcity of effective treatments against sepsis is daunting, especially under the contemporary standpoints on antibiotics resistance, entailing the development of alternative treatment strategies. Here, we describe the design and antibiotic adjuvant properties of a new lipopeptide-like pentamer, decanoyl-bis.diaminobutyrate-aminododecanoyl-diaminobutyrate-amide (C₁₀BBc₁₂B), whose sub-maximal tolerated doses combinations with inefficient antibiotics demonstrated systemic efficacies in murine models of peritonitis-sepsis and urinary-tract infections. Attempts to shed light into the mechanism of action using membrane-active fluorescent probes, suggest outer-membrane interactions to dominate the pentamer's adjuvant properties, which were not associated with typical inner-membrane damages or with delayed bacterial growth. Yet, checkerboard titrations with low micromolar concentrations of C₁₀BBc₁₂B exhibited unprecedented capacities in potentiation of hydrophobic antibiotics towards Gram-negative ESKAPE pathogens, with an apparent low propensity for prompting resistance to the antibiotics. Assessment of the pentamer's potentiating activities upon efflux inhibition incites submission of a hitherto unreported, probable action mechanism implicating the pentamer's de-facto capacity to hijack bacterial efflux pumps for boosting its adjuvant activity through repetitive steps including outer-membrane adhesion, translocation and subsequent expulsion.

Introduction

Sepsis represents one of the most notorious yet ill-treated medical conditions^1,2, annually affecting 49 million patients worldwide, with a towering mortality rate of 20%^3,4. Effective treatments are urgently needed as current strategies are limited to short-term immunomodulation^5,6,7 and broad-spectrum antibiotics administration^8,9,10, both of which do not adequately meet the challenge, hence allowing sepsis to persist as leading cause of death^3,4. Development of effective treatments is complicated, as they must overcome multiple obstacles pertaining to treatment onset, pathogens diversity, as well as variation in host response^1,2. This problem is exacerbated by increased prevalence of antibiotic resistance that further limits current treatments efficacies, particularly with regards to Gram-negative bacteria (GNB), against which, no new antibiotic classes have been successfully developed for over 50 years¹¹. Consequently, exploration of antibiotics combinations is frequently pursued by clinicians, sometimes based on trial and error. Alternatively, immune curbing by agents indifferent to pathogens and/or host variability, may offer a more versatile and potentially preferred treatment strategy. Thus, the ability to sequester contributing factors, such as lipopolysaccharides (LPS) that promote sepsis deterioration to septic-shock, would represent a desirable attribute of such agents.

Cationic antimicrobial peptides (AMPs) are sometimes considered as potential candidates for accomplishing this task. AMPs chemo-physical attributes were evolutionarily designed to selectively target bacterial membranes, including through interactions with anionic moieties of LPS, such as lipid A^12,13,14. Nevertheless, their clinical utilization is deemed challenging, namely due to their relatively short half-lives and host-toxicity upon systemic treatments, whereas peptidomimetic approaches are currently believed to minimize such drawbacks, imparting them with robustness and improved chances for successful clinical implementation¹⁵. Albeit, those characterized with membranolytic modes of action might in fact achieve the exact opposite outcome, as they too—appear to instigate unregulated LPS release. In this respect, antibiotic adjuvants (namely those using non-specific mechanisms) may provide an attractive treatment alternative¹⁶, as they can reinstate an antibiotic's efficacy as well as reduce high-dosage associated toxicity¹⁷. Adjuvants can also bestow potency upon Gram-positive-specific hydrophobic antibiotics towards GNB¹⁸, specifically when resistance emanates from their low translocation across the outer-membrane (OM)¹⁹. Moreover, owing to their mechanistic distinctions from antibiotics, adjuvants can be impervious to the documented resistance mechanisms, emphasizing an inherent advantage for their preferable utilization²⁰. One such group of AMP-mimetics is represented by short lipopeptide-like sequences, composed of amide-linked fatty acids and cationic amino acids²¹, which, owing to their simple yet modular structure, have recently shown considerable aptitude to facilitate fine-tuning of the chemo-physical properties and subsequent AMP-like biological attributes^22,23,24. Here, we sought out to investigate additional new analogs designed to function as adjuvants, through substitution of the cationic amino-acids and then attempted to elucidate the mechanism of action of the most promising emerging analog.

Results and discussion

C₁₀BBc₁₂B emerges as promising antibiotics adjuvant

Our previous attempts to design antibiotic adjuvants have focused on short lipopeptide-like sequences corresponding to the pentameric formula A_xCCa_yC; where "A_x" and "a_y", respectively represent the N-terminal acyl of length x (number of methyl groups) and an aminoacyl of length y, whereas "C" represents a cationic amino acid. Based on earlier findings^24,25, we abstained in the current study from incorporating an exceedingly hydrophobic acyl at the N-terminus, that could generate potent but non-selective antimicrobial lipopeptides, which in turn, might complicate their in-vivo systemic implementation due to toxicity phenomena such as hemolysis and unregulated LPS release. Instead, we used decanoic acid, which emerged from an analogous study²⁶ as potentially embodying the appropriate hydrophobicity for the sequences under present investigation. In parallel, we also attempted to optimize contributions emanating from the cationic residues, by adjusting their side-chain length (Fig. 1a).

We first attempted to detect hydrophobicity differences among the cationic analogs by comparing their elution properties, using a C₁₈ reversed-phase HPLC column. However, they all eluted between 45 and 46% hydrophobic solvent (acetonitrile), including upon co-injection of the four analogs, suggesting that the side-chains contribute very little to these molecules chromatographic behavior. This contrasted with previous observations where reducing or increasing the N-terminal acyl length by only 2 methylenes (e.g., C₁₂KKc₁₂K → C₁₀KKc₁₂K → C₈KKc₁₂K)²⁴ resulted in substantial hydrophobicity difference (as deduced from the fact that their elution required approximately 5% reduced or increased acetonitrile concentration, respectively). Additionally, assessment of self-assembly tendencies of these lipopeptide analogs (through measuring their light scattering properties) has also demonstrated little dissimilarities in their critical aggregation concentrations, which were all ≥ 100 µM.

Conversely, evaluation of the lipopeptides bioactive properties revealed similarities only between K-, O- and B-based analogs (Fig. 1b), whereas the P-based pentamer presented a divergent activity profile. Namely, C₁₀PPc₁₂P exhibited a hemolytic capacity somewhat more pronounced than that observed with its analogs (i.e., LC₅₀ = 26 versus > 100 µM, respectively). Additionally, when tested against 10 bacterial strains representing the four species of Gram-negative ESKAPE pathogens, the K-, O- and B-based analogs displayed high minimal inhibitory concentrations (MIC ≥ 50 µM), whereas C₁₀PPc₁₂P occasionally presented somewhat lower MIC values. Notably, C₁₀PPc₁₂P presented a lower selectivity profile (i.e., its MIC and LC₅₀ values were comparably scaled) which may be attributed to its side-chain's amine pKa, as it is less likely to be fully protonated at neutral pH (i.e., its β-NH₂ group pKa is 6.3²⁷ versus at least 10.4²⁸, for the three analogs). This could (at least partly) explain its similar potency against RBCs and bacterial cells, particularly since selectivity towards bacterial membranes is significantly charge-driven. Notably, no cytotoxicity towards cell-lines was observed at-least up to 50 µM.

Having established these analogs overall rather poor antibiotic activity against GNB, we next defined their capacities to function as adjuvants that sensitize bacteria to antibiotics. For this purpose, we determined the analogs ability, at a sub-inhibitory concentration (10 µM) to potentiate erythromycin and rifampin (representing two antibiotic families that are normally ineffective against GNB, namely due to their hydrophobicity) using E. coli as representative species. As shown in Table 1, all four analogs presented substantial potentiation capacities, although generally, potency appeared to increase as the cations transitioned from K to B and then decreased with P. Of note, despite the weaker growth-inhibitory activity of C₁₀BBc₁₂B (Fig. 1b), this pentamer exhibited the strongest potentiating activities (Table 1). This is namely evidenced by its lower calculated fractional inhibitory concentration index, compared with the next most potent analog (i.e., 0.2 versus 0.4, respectively for C₁₀BBc₁₂B and C₁₀PPc₁₂P).

Table 1 E. coli sensitization to antibiotics by adjuvants.

Full size table

Since cyclization of AMPs was found to improve their potency, we similarly produced and tested the corresponding head-to-tail cyclic analogs of the four pentamers. As depicted in Table 1, while maintaining considerable potencies, the cyclic analogs presented substantially lower SF values than their linear counterparts. This finding suggests that structural rigidity contributes to greater antimicrobial potency, whereas flexibility appears to promote stronger adjuvant properties.

Table 1 also compares the pentamers sensitization factors (SF) values with those reported for SPR741, a promising cyclic polymyxin B nonapeptide derivative³¹ (PMBN) under clinical investigation³². Interestingly, when assessed in another study³⁰ for its capacities to potentiate various antibiotics against 3 GNB species, SPR741 revealed SF values seldom exceeding 1000 folds which, in the case of erythromycin, we found quite similar to those of C₁₀BBc₁₂B (using the same E. coli strain). In the case of rifampin however, although both adjuvants displayed even higher SF values, C₁₀BBc₁₂B revealed to be substantially more potent.

A broader scope of C₁₀BBc₁₂B potentiation capacities is shown in Fig. 2, indicating that the pentamer is endowed with a similarly exquisite capability for sensitizing all four Gram-negative representatives of ESKAPE pathogens tested, as observed with both erythromycin and rifampin. The isobolograms (presented in panels a and b) display geometries indicative of definite synergistic relationships and in most cases, C₁₀BBc₁₂B has potentiated the antibiotics to a point requiring concentrations well-below their respective resistance breakpoints (i.e., 8 and 1 µg/ml respectively for erythromycin and rifampin, as defined against Staphylococci)³³. For example, the pentamer reduced erythromycin's inhibitory concentrations against E. coli and K. pneumoniae from 128 and 512 µg/ml to 0.125 and 0.250 µg/ml (i.e., SF values of 1024 and 2048, respectively). Likewise, rifampin's MIC against these species was reduced to below 1 ng/ml, reflecting an increased sensitization efficiency of 65,000 and 130,000 folds, respectively. Such unprecedented values strengthen the proposed stature of C₁₀BBc₁₂B as an exceptionally potent antibiotic adjuvant.

Pathogens sensitization is dissociated from emergence of resistance

To assess selective pressure effects on the observed bacterial sensitization to antibiotics, we compared the rates of antibiotic-resistance development by A. baumannii which occupies the top of the urgent category in the latest CDC's antibiotics resistance threats report³⁴. Panels c and d show that in presence of C₁₀BBc₁₂B, the MIC of either antibiotic has not increased by more than 2 folds, which corresponds to the inherent variance of the microdilution technique used during the subculture passages and thus can be regarded as practically unaltered. Conversely, in absence of C₁₀BBc₁₂B, antibiotics' MIC values have increased by 128 and 4 folds, respectively for erythromycin and rifampin (i.e., from 64 to 8,192 µg/ml and from 2 to 8 µg/ml, respectively). This dissimilar increase maybe ascribed to the antibiotics differential modes of action (i.e., bacteriostatic versus bactericidal)³⁵ or to their respective predominant resistance mechanism (i.e., efflux pumps over-expression³⁶ or rpoB mutations³⁷). Regardless, the fact that in presence of C₁₀BBc₁₂B the antibiotics' MIC remained effectively constant, implies that the pentamer has effectively bypassed bacterial aptitudes for developing antibiotic-resistance (at least throughout the assay duration). While the molecular basis is yet to be elucidated, it is worth mentioning that similar assessment was recently reported for SPR741³² on E. coli³⁸. Moreover, as despite the pentamer's greater synergistic potency and the consequently greater evolutionary pressure exerted on resistance development³⁹, resistance has not materialized, thereby highlighting potential advantages of C₁₀BBc₁₂B-based therapies.

C₁₀BBc₁₂B performs as adjuvant In-Vivo to protect mice from infections

Towards determining the potential of C₁₀BBc₁₂B to resolve resilient GNB infections, we used a modified peritonitis-sepsis infection model to verify whether bacteria that were exposed to the pentamer prior to administration to mice, would (in principle) be able to affect the disease course, possibly via LPS neutralization, considering that immune activation by LPS is an underlying factor for sepsis deterioration. Thus, bacteria briefly exposed to C₁₀BBc₁₂B (10 µM in PBS, a concentration known to affect outer-membrane (OM) permeability but does not alter bacterial proliferation rates, as will be shown in Fig. 4) were administered intraperitoneally to neutropenic mice and mortality was recorded for three days thereafter, as compared to control mice infected by the same culture pre-treated with PBS vehicle. As shown in Fig. 3a1, bacteria that were exposed to the pentamer have delayed the onset of mice mortality and reduced the overall lethality rate, thereby reflecting the pentamer's potential ability to interfere with the sepsis process upon treating infected mice, assuming proper pharmacokinetic behavior would be achieved. Encouraged by this observation, we next prepared to assess the pentamer's ability to affect sepsis (using the unmodified peritonitis-sepsis model) upon subcutaneous administration to infected mice of a sub-maximal tolerated dose (MTD).

Thus, MTD determination after administration of increasing doses (i.e., 0, 20 and 40 mg/kg C₁₀BBc₁₂B) to normal mice revealed no apparent physiological signs of distress for any of the mice, from the moment of injection throughout a seven-day monitoring period (i.e., MTD was estimated > 40 mg/kg). This represents a significant improvement compared to its analog C₁₀OOc₁₂O²², for which transient signs of distress were observed in a mouse (score of 3 out of 6) and mortality of another mouse was recorded within an hour after administering the 40 mg/kg dose (i.e., estimated MTD was > 20 but < 40 mg/kg). As the B-based pentamer's MTD is comparable to that reported for the last-resort antibiotic PMB⁴⁰, this finding suggests that C₁₀BBc₁₂B might offer an improved safety profile given its molecular attributes as small molecule and milder, non-membranolytic putative mechanism of action (as further addressed below).

Next, we evaluated the lipopeptide's ability to affect survival of infected neutropenic mice. Figure 3a2 depicts the mice survival rates upon monotherapy or/and combination-therapies. Thus, while the control mice response to infection has evolved similarly to the experiment shown in panel a1 (i.e., 80% mortality in control mice was reached at two–three days post-infection, using similar inoculum size) mice treated with C₁₀BBc₁₂B or rifampin displayed roughly comparable (40 and 50%, respectively) improved survival rates, as compared to the vehicle control, whereas the combination treatment reached 90% survival. The fact that C₁₀BBc₁₂B showed some efficacy even in absence of rifampin evokes our previous findings^22,29 where using a similar infection model and treatment, C₁₀OOc₁₂O has also exhibited significant monotherapy efficacy. While the molecular basis for the pentamers' abilities to prevent mice death in absence of an exogenous antibiotic is yet to be elucidated, we provided various lines of evidence arguing for the possible role played by one or more endogenous antimicrobials that may have substituted for rifampin's role. If that were to be the case, one would be allowed to predict a more potent antimicrobial performance of C₁₀BBc₁₂B in treating infections of wild animals (as opposed to laboratory animals such as the mice used herein) since they are normally endowed with a more robust innate immunity.

Figure 3 (panel a3) provides evidence for considerable systemic efficacy even under harsher infection conditions (i.e., when mice were infected with a higher inoculum size) where lethality of control mice has reached 100% already on day one and mice treated with C₁₀BBc₁₂B or rifampin displayed virtually no efficacy. Under these conditions, the combination treatment managed to increase the survival rates from 0 to 40%, thus implying a synergistic outcome, reminiscent of the synergy observed in terms of SF values (Fig. 2a, b).

Next, we assessed the pentamer's ability to affect the course of another disease, using the urinary tract infection (UTI) model, where, uro-pathogenic E. coli bacteria were administered by intra-urethral route and the infected mice treated with either C₁₀BBc₁₂B or rifampin or with a combination thereof, and bacterial loads in bladder and kidneys were quantified 24 h post-infection. To determine efficacy, we assessed different treatment regimens, including an initial single dose of 7.5 or 12.5 mg/kg C₁₀BBc₁₂B administered 1 h post infection, but found these regimens to be essentially ineffective, whether administered alone or in combination with rifampin. However, administration of four doses of C₁₀BBc₁₂B within a 24-h period, have generated a significant efficacy upon combination with rifampin. Thus, while no reduction in bacterial load was observed in bladders with any of the tested treatments (Fig. 3b1), the combination treatment has reduced the kidneys bacterial load, as evidenced by complete bacterial eradication (or prevention of colonization altogether) in 80% of the treated mice (Fig. 3b2).

Towards establishing cause and effect relationships, we next attempted to correlate these efficacy outcomes with the circulating pentamer's levels, in the respective tissues of interest. Figure 3c1, c2 present data summarizing the biodistribution analysis showing that C₁₀BBc₁₂B presence overlapped with the efficacies outlined in Fig. 3a, b, respectively. Thus, similarly to its analogs²², the subcutaneous administration of C₁₀BBc₁₂B resulted in a steep increase of its circulating concentrations (reaching its maximum after 30–60 min) followed by a shallower decline that ultimately cleared most of the lipopeptide from the bloodstream after ~ 180 min. Importantly, C₁₀BBc₁₂B maintained antibiotics potentiating concentrations (i.e., ≥ 2.5 µg/ml) for > 2 h post-adjuvant administration. Likewise, quantification of C₁₀BBc₁₂B in bladder and kidneys, revealed negligible amounts in the bladder, whereas the pentamer was readily quantifiable in kidneys for at least 3 h post-inoculation. Therefore, these findings align well with those observed in Fig. 3, in the sense that treatment efficacies are correlated with the adequate pentamer's presence.

Antibiotics potentiation is mediated by C₁₀BBc₁₂B interactions with the OM

Towards better understanding the synergistic mechanism, we compared individual growth kinetics to determine contributions of each antimicrobial and assessed the type and extent of implicated membrane damages, assuming that low OM-permeability underlies the observed antibiotics inefficiencies by impeding their intracellular accumulation. Figure 4a shows that at synergistic concentrations (i.e., 10 µM C₁₀BBc₁₂B and 1 µg/ml erythromycin or 20 ng/ml rifampin) all individual proponents were unable to significantly alter bacterial proliferation (i.e., growth curves obtained for untreated control and individual treatments, were virtually undistinguishable) whereas upon combining treatments, bacterial proliferation was arrested for at least 6 h, followed by bacterial death levels that nearly eradicated the cultures at the 24 h endpoint. Using equivalent conditions, similar growth curves have also characterized K. pneumoniae, P. aeruginosa and A. baumannii (data not shown). Importantly, while sub-inhibitory concentrations of some reported antibiotic potentiators (such as C_14(ɷ5)OOc₁₀O²³ or PMBN⁴¹) have transiently inhibited bacterial growth in absence of antibiotics, the fact that C₁₀BBc₁₂B is devoid of this attribute cements our proposed classification as adjuvant. Also, C₁₀BBc₁₂B combinations with erythromycin or rifampin exhibited similar behaviors—despite the antibiotics distinct modes of action, hence providing additional support to the notion that their potentiation maybe mechanistically related, where the pentamer plays a facilitator role, in both cases. To test this postulate, we next assessed the extent of OM damage using N-phenyl-1-naphthylamine (NPN) fluorescence measurements (Fig. 4). As shown in panel b1, C₁₀BBc₁₂B, like PMB (deemed gold-standard OM-permeabilizer)^12,42, increased E. coli's OM permeability to NPN in a dose-dependent manner, albeit in a milder fashion. Validation of these findings is provided by the observation that high concentrations of MgCl₂ have attenuated the NPN fluorescence for both agents, correspondingly. Thus, the resulting fluorescence reduction (i.e., almost complete for C₁₀BBc₁₂B and much less for PMB) enforces the concept that C₁₀BBc₁₂B and PMB differ in their affinities towards LPS. This notion was further corroborated using dansyl-PMB (DPMB) competition experiments (Fig. 4 panel b2) by confirming the inferior ability of C₁₀BBc₁₂B to displace the LPS-bound DPMB (the relevance of this affinity difference will be addressed while discussing Fig. 6).

Another experiment stressing mechanistic difference(s) between these lipopeptides (C₁₀BBc₁₂B and PMB) is provided through their ability to affect cytoplasmic membrane (CM) permeability. Unlike PMB whose bactericidal activity was associated with a rapid CM-depolarization¹² (Fig. 4 panel b3), C₁₀BBc₁₂B was clearly unable to affect the trans-membrane potential (TMP) at the tested concentration range (i.e., up to 10 µM). The fact that a more hydrophilic analog C₈BBc₁₂B (data not shown) displayed dose–response depolarization traces that are indistinguishable (i.e., identical to that shown in Fig. 4 panel b3), supports the notion that both derivatives are indeed devoid of some minimal attribute (hydrophobicity?) required for initiating CM-damages.

The lack of observable CM damage upon C₁₀BBc₁₂B interaction with GNB (panel 4b3) is consistent with the kinetics results presented in panel 4a, since if such damage was to occur, some growth delay should have been apparent, as was observed with C_14(ɷ5)OOc₁₀O²³ and PMBN⁴¹ as well as with C₁₀KKc₁₂K²⁴ and to a lesser extent with C₁₀OOc₁₂O²². These observations (i.e., experiments linking OM permeabilization by C₁₀BBc₁₂B to its antibiotics potentiation activity) along with the results establishing the weaker interactions of C₁₀BBc₁₂B with both membranes in comparison with the bactericidal PMB (panels b1–b3) hence render mechanistically puzzling its greater capacity to sensitize GNB to rifampin. Of note, the fact that the displacement profile of C₁₀BBc₁₂B resembled more that of PMBN than PMB (panel b2), suggests that lower LPS affinities promote stronger adjuvant properties.

Implication of efflux machinery in antibiotics potentiation

While C₁₀BBc₁₂B appears to hold mechanistic attributes similar to those of polymyxins, we find that these lipopeptides are distinguishable by various aspects (besides the aforementioned differences) including susceptibility to undergo efflux. When comparatively assessed against the isogenic pair of wild-type E. coli Ag100 and its efflux deficient mutant Ag100a (ΔacrAB) a higher potency of C₁₀BBc₁₂B (eightfold reduction in MIC value) was observed against the mutant strain (Table 2). Similar relationships were recorded with another isogenic pair of Salmonella enterica serovar Typhimurium. These outcomes would sit well with the notion that C₁₀BBc₁₂B is an efflux substrate, very much as previously proposed for its analogs C₁₀KKc₁₂K²⁶ and C₁₀OOc₁₂O²⁹, unlike C₁₄OOc₁₂O²³ or C₁₄KKc₁₂K²⁴. Accordingly, the polymyxins (e.g., PMB or colistin), often described as unlikely efflux-substrates^43,44,45 are in fact efficient CM-destabilizers that swiftly dissipate the TMP, thereby obstructing the proper proton-dependent function of resistance-nodulation-division (RND) efflux pumps, including the AcrAB-TolC system commonly expressed in Enterobacteriaceae.

Table 2 Effect of RND pumps on growth-inhibitory activity.

Full size table

Thus, although both PMBN and C₁₀BBc₁₂B may act as antibiotic adjuvants by increasing OM-permeability, we find that they differ in relation to how they affect the TMP and how they are affected by efflux: the former causes TMP dissipation, possibly inactivating proton-dependent efflux (including of itself)⁴⁷ whereas C₁₀BBc₁₂B appears relatively reluctant to interact with the CM despite its hydrophobic and cationic attributes, thereby sustaining de-facto, its availability for efflux from the periplasm or from superficial adhesion to the CM (as proposed for C₁₀KKc₁₂K²⁶ but not C₁₄KKc₁₂K²⁴).

Another distinguishing aspect emanated from the lipopeptides divergent behavior in presence of efflux pump inhibitors (EPIs). Since PMBN was reported to synergize with EPIs in potentiating antibiotics activity⁴¹, we verified whether C₁₀BBc₁₂B potentiation could be similarly enhanced in presence of EPIs especially since, in the pentamer's case, efflux function stands presumably unaffected. However, introduction of EPIs appears to rather dampen the pentamer's capacity for antibiotics potentiation. Thus, towards isolating relationships between C₁₀BBc₁₂B, EPI and efflux machinery, we used rifampin (instead of erythromycin) owing to its non-susceptibility for efflux by RND pumps⁴⁸ (and in Table 2). Figure 5a shows that C₁₀BBc₁₂B SF values, as determined in absence of the EPI phenylalanine-arginine β-naphthylamide (PAβN)^49,50, were in fact greater than those obtained in its presence, thereby suggesting an antagonistic relationship between C₁₀BBc₁₂B and PAβN or even another EPI^49,51, unlike PMBN's⁴¹. It is ought to be mentioned that while functioning as efflux pumps inhibitors, these EPIs ^52,53 were additionally reported to increase OM permeability (as might also be inferred from our observations, as depicted in Fig. 5a). Unfortunately therefore, as this dual mechanism of action of PAβN (i.e., pump inhibitor and OM permeabilizer), complicates the assignment of either one of its functions to the antagonistic relationship with C₁₀BBc₁₂B, we attempted to circumvent this challenge by using an alternative approach for limiting efflux function, and depleted the fuel required for proper function of RND pumps (the proton motive force) by introducing the ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP)^54,55. As shown in Fig. 5b, CCCP has diminished the OM-permeabilization exerted by C₁₀BBc₁₂B. Importantly, NPN fluorescent signals obtained with the untreated control and with the CCCP-treated control (without lipopeptide) were practically identical, indicating that CCCP affected the proton motive force, without compromising OM integrity. These findings therefore support a scenario in which proper efflux function could boost OM-permeabilization by C₁₀BBc₁₂B.

Reiterated Efflux-Propelled OM Interactions Might Boost C₁₀BBc₁₂B Potency

The data collected so far (particularly observations detailed in Figs. 4 and 5) insinuate mechanistic aspects that might explain the extraordinary potentiation capacities of C₁₀BBc₁₂B. In our understanding, they could be rationalized to reflect a cyclic scenario consisting of three main steps, as depicted in Fig. 6.

1.
Adhesion: As described for PMB by the self-promoted uptake theory⁵⁶, electrostatic attraction would initially lead to C₁₀BBc₁₂B adherence to anionic OM components (namely LPS). This interaction effectively displaces LPS-bound bivalent cations (that normally limit lateral motion by "gluing" adjacent lipid-A molecules) thereby expanding the monolayer fluidity. This effect is likely exacerbated by the lipopeptide's larger molecular volume that further increases the intermolecular distances, thereby leading to transient crack formations, through which hydrophobic molecules may sift inwards.
2.
Translocation: These presumably short bursts of membrane disruption events could nevertheless eventually mount to the translocation of otherwise excluded hydrophobic compounds (exemplified in this work by rifampin and erythromycin) thereby facilitating their interaction with cytoplasmic targets. Concomitantly, this resultant OM-permeabilization also promotes the translocation of additional C₁₀BBc₁₂B molecules.
3.
Expulsion: After translocating into the periplasm, the pentamer's fate can theoretically follow several routes, including exit the periplasm autonomously (unlikely, since it would require diffusion opposing the lipopeptide's concentration gradient), interaction with periplasmic constituents including the CM outer leaflet and/or expulsion by efflux. Likely therefore, at this stage, C₁₀BBc₁₂B would be simultaneously attracted to both the CM anionic phospholipids and to the efflux pump hydrophobic pocket^57,58,59. Here too, the lipopeptide's moderate hydrophobicity might serve as a key determinant for the subsequent outcome, as it was shown that hydrophobic analogs (such as C₁₄KKc₁₂K²⁴) might escape extrusion by efflux pumps via strong interactions and deep insertion within the CM^60,61, where they would instigate damages to various extents^24,62. In this respect, the pentamer's hydrophobicity appears to be sufficiently low so as to restrict itself to a superficial CM-adherence at most, which would limit its escape from efflux (or at least prolong its unbound state in the periplasm, which increases its chances for expulsion). Notably, the intact TMP sustains the pump's ability to expel the pentamer, which now would be able to re-adhere to the OM and repeat the cycle all over again.

Figure 6

Search This Blog

Adult Vaccinations

Is Your Risk of Being Sued Climbing